ENB-003

▎药明康德内容团队编辑本期看点1. T细胞诱导剂CUE-101单药作为HPV阳性头颈部鳞状细胞癌（HNSCC）患者的二线及二线以上治疗，患者的中位总生存期（OS）较接受免疫检查点抑制剂单药治疗患者的历史报告生存期延长超过一倍。2. 肿瘤免疫治疗新药Galinpepimut-S联用帕博利珠单抗治疗Wilms肿瘤1（WT1）阳性铂耐药卵巢癌患者的早期临床数据亮眼，患者的无进展生存期（PFS）延长41%，中位OS达18.4个月。3. 选择性内皮素B受体（ETBR）抑制剂ENB-003与帕博利珠单抗联用治疗转移性铂耐药卵巢癌患者，疾病控制率（DCR）高达80%。药明康德内容团队整理CUE-101：公布1期临床试验数据 Cue Biopharma公司评估了其基于白细胞介素-2（IL-2）的T细胞诱导剂CUE-101作为单一疗法以及与帕博利珠单抗联用治疗复发性/转移性HPV阳性HNSCC患者的效果。结果显示，CUE-101联用帕博利珠单抗一线治疗复发/转移性HNSCC者的客观缓解率（ORR）为47%，DCR为65%。PD-L1低表达患者的ORR为56%。接受CUE-101单药作为二线及二线以上治疗的患者，中位OS为20.8个月，而在使用免疫检查点抑制剂作为二线治疗的临床试验（CheckMate 1411和KEYNOTE-040）中，患者的历史报告生存期约为8个月（分别为7.5个月和8.4个月）。安全性方面，CUE-102在剂量递增试验阶段未观察到剂量限制性毒性（DLT），也未达到最大耐受剂量。Galinpepimut-S：公布1/2期临床试验数据 SELLAS Life Sciences Group公司公布了其靶向WT1蛋白的潜在“first-in-class”肿瘤免疫治疗新药Galinpepimut-S（GPS）联用PD-1抑制剂帕博利珠单抗用于治疗WT1阳性铂耐药卵巢癌患者的1/2期临床试验的最终结果。该药由4条多肽链构成，抗原表位多达25个，适用于全球范围内绝大多数人类白细胞组织相容性抗原（HLA）类型，能够激发自身免疫系统对WT1抗原强烈的免疫反应。研究结果显示，GPS联合疗法的中位OS为18.4个月。相比之下，KEYNOTE-028研究中，此类患者的中位总生存期（OS）为13.8个月，化疗标准治疗的中位OS为11-14个月。此外，GPS联合治疗产生了WT1特异性T细胞免疫反应，在亚组患者中与生物标志物IFNγ和MIP1β呈正相关。患者的PFS延长了41%，差异具有统计学意义（P=0.025）。ENB-003：公布1b期临床试验数据 ENB Therapeutics公司公布了其在研选择性ETBR抑制剂ENB-003与帕博利珠单抗联用治疗难治性晚期实体瘤患者的1b期临床试验的顶线数据。在临床前研究中，ENB-003提高了CAR-T细胞疗法和PD-1抑制剂在多种癌症类型的实体瘤中的疗效。此次公布的数据显示，ENB-003与帕博利珠单抗联用的耐受性良好，5例微卫星稳定（MSS）的转移性铂耐药卵巢癌患者的ORR为40%，DCR为80%。2例获得部分缓解（PR）的患者的肿瘤负荷分别减少了95%和33%。8个月的无进展生存率为60%。相比之下，PD-1抑制剂单药治疗此类患者的ORR为8%，DCR为22%，6个月的无进展生存率为20%。MDNA11：公布1/2期临床试验的新数据Medicenna Therapeutics公司公布了其下一代长效IL-2超级激动剂MDNA11治疗晚期实体肿瘤的新临床结果。MDNA11具有优秀的CD122（IL-2受体β）结合作用，而没有CD25（IL-2受体α）亲和力，从而能优先刺激癌症杀伤效应T细胞和NK细胞。此次公布的结果显示，MDNA11治疗在所有队列中的耐受性良好，继续表现出持久的抗肿瘤免疫作用。MDNA11已使3名黑色素瘤患者获得了5个月至18个月的持久疾病稳定（SD），并且这些患者在免疫检查点抑制剂治疗失败后，肿瘤大小仍有缩小。1例转移性胰腺导管腺癌患者的3个病灶（2个靶病灶和1个非靶病灶）完全消褪。一例皮肤黑色素瘤患者的靶淋巴结病灶在第12周时减少了70%。这两位患者目前均为PR。IMA203：公布1期临床试验数据Immatics公司公布了其在研T细胞受体T细胞（TCR-T）疗法IMA203治疗复发性和/或难治性实体瘤患者的1期试验的中期数据。IMA203是由Immatics专有ACTengine平台所开发的TCR-T细胞，靶向由HLA-A*02呈递的黑素瘤抗原PRAME。PRAME是一种在各种实体瘤中经常表达的蛋白质。此次数据公布以黑色素瘤患者为重点，IMA203 GEN1 TCR细胞疗法的1a期和队列A的耐受性良好，黑色素瘤患者按推荐的2期剂量接受治疗后，确认的ORR为50%；一些患者持续缓解超过15个月，中位随访时间为14.4个月时仍未达到中位缓解持续时间。IMA203CD8是该公司的第二代产品，药理作用增强，作用模式也与IMA203有所区别。接受IMA203CD8 GEN2 TCR细胞疗法治疗的患者（队列C）的耐受性可控，剂量递增研究仍在进行中。在接受剂量3和剂量4治疗的患者中观察到初步的临床活动，确认的ORR分别为56%（5/9）和58%（7/12）；7个获得缓解的患者中有6个还保持着缓解，最长已缓解超过12个月。▲患者特征和IMA203的抗肿瘤活性概述（图片来源：参考资料[31]）此外，研究人员在非黑色素瘤患者中也观察到了疗效信号，包括卵巢癌、子宫癌、非小细胞肺癌和三阴性乳腺癌。SRK-181：公布1期临床试验数据Scholar Rock公司公布了其旨在克服晚期癌症患者对检查点治疗的耐药性的单克隆抗体SRK-181的1期概念验证试验数据。TGFβ1是在许多人类肿瘤类型中表达的主要TGFβ亚型。研究表明，TGFβ1是免疫抑制肿瘤微环境的关键贡献者。SRK-181是一种选择性的潜在的TGFβ1激活抑制剂，与抗PD-1/PD-L1疗法联合使用时，有潜力克服检查点治疗耐药问题，同时可能避免其他非选择性TGFβ抑制方法存在的心脏毒性。此次公布的数据显示，SRK-181联用帕博利珠单抗治疗此前已接受过多线治疗的透明细胞肾细胞癌（ccRCC）患者具有良好的抗肿瘤活性，且患者的耐受性良好。患者的ORR为21.4%，疾病控制率为57%，生物标志物数据为多种肿瘤类型提供了机制证明。CUE-102：公布1期临床试验数据Cue Biopharma公司公布了CUE-102的初步临床数据。CUE-102是一种由两个呈递WT1肽的人白细胞抗原（HLA）分子、四个亲和力减弱的IL-2分子和一个效应减弱的人免疫球蛋白G（IgG1）Fc结构域组成的新型生物制品，被开发作为单一疗法治疗WT1阳性复发/转移性癌症患者。WT1已知在多种实体瘤和血液系统恶性肿瘤中过度表达，包括胃癌、胶质母细胞瘤、胰腺癌、卵巢癌、子宫内膜癌、乳腺癌、肺癌、结直肠癌和急性髓系白血病等。此次公布的结果显示，CUE-102在4 mg/kg和2 mg/kg剂量下的DCR分别为75%和80%，其中有两名患者的肿瘤缩小了30%和29%。Itolizumab：公布1b期临床试验数据Equillium公司公布了其潜在“first-in-class”的CD6单克隆抗体itolizumab治疗狼疮性肾炎患者的早期临床数据。数据显示，在霉酚酸酯（MMF）和皮质类固醇的基础上加用皮下给药的itolizumab，接受28周治疗的受试者的完全缓解（CR）率为40%（6/15），PR率为33%(5/15)，73%的受试者的尿蛋白肌酐比值（UPCR）下降超过50%。此外，itolizumab具有良好的安全性和耐受性。HCW9218：公布1期临床试验数据HCW Biologics公司公布了其皮下注射的双功能融合蛋白复合物HCW9218在至少两线治疗失败的实体瘤患者中的疗效。HCW9218创新性地将TGF-β受体和IL-15结合在一起，前者可中和肿瘤分泌的一种免疫抑制细胞因子，后者则是一种强效细胞因子，可刺激自然杀伤（NK）细胞和CD8+ T细胞的细胞毒性。此次公布的结果显示，50%（4/8）的患者实现了SD，患者的病情稳定期超过6个月。卵巢癌患者的疗效优于其他癌种的患者，SD率为66%（2/3）。HCW9218可强烈促进患者血液中NK和T细胞的增殖和活化，但不会引起细胞因子释放综合征。此外，未观察到肝酶升高。SD-101：公布1期临床试验数据TriSalus Life Sciences公司公布了其C类TLR9激动剂SD-101联合纳武利尤单抗治疗葡萄膜黑色素瘤伴肝转移患者的初步数据。该研究旨在评估由FDA批准的TriNav输液系统通过该公司专有的压力赋能的递送（Pressure-Enabled Drug Delivery，PEDD）方法递送SD-101是否可以改善全身性免疫检查点抑制剂治疗葡萄膜黑色素瘤伴肝转移患者的疗效。研究结果显示，当通过PEDD方法进行给药时，SD-101联合纳武利尤单抗使大多数患者的肿瘤微环境得到调节，这与此前在针对胰腺癌患者的研究中观察到的结果一致。SD-101联用纳武利尤单抗的最佳生物制品剂量为2 mg，患者的中位无进展生存期为11.7个月，DCR为81%。大家都在看药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料（可上下滑动查看）[1] Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal. Retrieved November 7, 2023, from https://www.globenewswire.com/news-release/2023/11/03/2772977/0/en/Mendus-Phase-1-vididencel-clinical-trial-results-in-AML-and-high-risk-MDS-patients-published-in-peer-reviewed-medical-journal.html[2] Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting. Retrieved November 7, 2023, from https://www.globenewswire.com/news-release/2023/11/03/2773319/0/en/Molecular-Partners-Presents-Updated-Positive-Data-from-Ongoing-Phase-1-Trial-of-MP0317-FAP-X-CD40-Monotherapy-in-Patients-with-Advanced-Solid-Tumors-at-the-2023-SITC-Annual-Meeting.html[3] Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023. Retrieved November 7, 2023, from https://www.globenewswire.com/news-release/2023/11/03/2773318/0/en/Cue-Biopharma-Presents-New-Positive-Data-from-Phase-1-Trials-of-CUE-101-in-Head-and-Neck-Cancer-and-CUE-102-in-Wilms-Tumor-1-Positive-Cancers-at-SITC-2023.html[4] Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability. Retrieved November 7, 2023, from https://www.businesswire.com/news/home/20231103455994/en[5] Sosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial. Retrieved November 7, 2023, from https://www.globenewswire.com/news-release/2023/11/05/2773680/0/en/Sosei-Heptares-Partner-Pfizer-Progresses-Its-GLP-1-Receptor-Agonist-PF-06954522-into-a-Phase-1-Trial.html[6] Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications. Retrieved November 7, 2023, from https://www.businesswire.com/news/home/20231104543355/en[7] Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis. Retrieved November 7, 2023, from https://www.globenewswire.com/news-release/2023/11/06/2773926/0/en/Cabaletta-Bio-Receives-FDA-Clearance-of-CABA-201-IND-Application-for-Treatment-of-Generalized-Myasthenia-Gravis.html[8] IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. Retrieved November 7, 2023, from https://www.globenewswire.com/news-release/2023/11/06/2774075/0/en/IN8bio-Presents-Biologic-Correlative-Data-from-the-INB-200-Phase-1-Trial-in-Newly-Diagnosed-Glioblastoma-at-the-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting.html[9] 23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1. Retrieved November 7, 2023, from https://www.globenewswire.com/news-release/2023/11/06/2774033/0/en/23andMe-Announces-Updated-Safety-and-Preliminary-Efficacy-Data-From-the-Phase-1-2a-Study-of-23ME-00610-an-Investigational-Antibody-Targeting-CD200R1.html[10] Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology. Retrieved November 7, 2023, from https://www.businesswire.com/news/home/20231106290948/en[11] SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting. Retrieved November 7, 2023, from https://www.globenewswire.com/news-release/2023/11/06/2774155/0/en/SELLAS-Life-Sciences-Presents-Positive-Key-Immunobiological-and-Clinical-Data-from-Phase-1-2-Trial-of-Galinpepimut-S-GPS-in-Combination-with-Keytruda-in-WT1-Platinum-Resistant-Adva.html[12] Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Retrieved November 7, 2023, from https://ir.medicenna.com/news-releases/news-release-details/medicenna-announces-promising-single-agent-response-and[13] AAO Late-Breaking: Kiora’s Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa. Retrieved November 7, 2023, from https://kiorapharma.reportablenews.com/pr/kiora-presents-abacus-data-at-aao[14] TILT Biotherapeutics Announces Positive Clinical Data on Lead Asset TILT-123 at Society for Immunotherapy of Cancer 2023. Retrieved November 7, 2023, from https://www.globenewswire.com/news-release/2023/11/06/2773739/0/en/TILT-Biotherapeutics-Announces-Positive-Clinical-Data-on-Lead-Asset-TILT-123-at-Society-for-Immunotherapy-of-Cancer-2023.html[15] Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab. Retrieved November 7, 2023, from https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-prurigo-nodularis[16] Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a TumorActivated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors. Retrieved November 7, 2023, from https://ir.xiliotx.com/node/7816/pdf[20] Tallac Presents First Clinical Data for TAC-001 at SITC 2023. Retrieved November 7, 2023, from https://www.businesswire.com/news/home/20231103234375/en/[21] CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with Immunotherapy CDR404 for Treatment of Solid Tumors at SITC 2023. Retrieved November 7, 2023, from https://www.cdr-life.com/news_item/cdr-life-presents-findings-from-two-studies-in-preparation-of-phase-1-trial-with-immunotherapy-cdr404-for-treatment-of-solid-tumors-at-sitc-2023/[22] BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent. Retrieved November 7, 2023, from https://www.accesswire.com/799347/bioinvent-presents-positive-data-at-sitc-from-clinical-phase-12a-trial-of-bi-1808-as-single-agent[23] Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting. Retrieved November 7, 2023, from https://investors.senseibio.com/news-releases/news-release-details/sensei-biotherapeutics-reports-favorable-clinical-data-sns-101[24] HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023. Retrieved November 7, 2023, from https://ir.hookipapharma.com/news-releases/news-release-details/hookipa-pharma-presents-positive-biomarker-and-translational[25] ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023. Retrieved November 7, 2023, from https://www.globenewswire.com/news-release/2023/11/03/2773393/0/en/ImCheck-Presented-Updated-Positive-Data-from-Phase-I-IIa-EVICTION-2-Trial-of-ICT01-in-Combination-with-Low-dose-IL-2-at-SITC-2023.html[26] Autobahn Therapeutics Announces Positive Topline Results from Phase 1 Study of ABX-002, its Lead Oral Treatment for Major Depressive Disorder. Retrieved November 7, 2023, from https://www.businesswire.com/news/home/20231107741595/en[27] Gate Neurosciences Announces Positive Topline Human EEG Biomarker Results Demonstrating Dose-Dependent Target Activation in Phase 1 Study of Apimostinel. Retrieved November 7, 2023, from https://www.businesswire.com/news/home/20231107912541/en[28] ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023. Retrieved November 7, 2023, from https://www.businesswire.com/news/home/20231107964841/en[29] Grace Science Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Phase 1/2/3 Trial for the Treatment of NGLY1 Deficiency with GS-100, an AAV9 NGLY1 Gene Therapy. Retrieved November 8, 2023, from https://www.businesswire.com/news/home/20231106501186/en/Grace-Science-Announces-FDA-Clearance-of-Investigational-New-Drug-IND-Application-to-Initiate-a-Phase-123-Trial-for-the-Treatment-of-NGLY1-Deficiency-with-GS-100-an-AAV9-NGLY1-Gene-Therapy[30] Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting. Retrieved November 8, 2023, from https://www.globenewswire.com/news-release/2023/11/08/2776105/0/en/Investigator-Sponsor-of-HCW-Biologics-Phase-1-Clinical-Trial-Presented-Human-Data-Readout-and-Anti-Cancer-Mechanism-of-Action-of-HCW9218-at-38th-SITC-Annual-Meeting.html[31] Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial. Retrieved November 8, 2023, from https://www.globenewswire.com/news-release/2023/11/08/2776060/0/en/Immatics-Reports-Interim-Clinical-Data-from-ACTengine-IMA203-and-IMA203CD8-TCR-T-Monotherapies-Targeting-PRAME-in-an-Ongoing-Phase-1-Trial.html[32] Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research. Retrieved November 8, 2023, from https://ir.replimune.com/news-releases/news-release-details/replimune-presents-updated-data-rp2-uveal-melanoma-during[33] Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis. Retrieved November 8, 2023, from https://www.globenewswire.com/news-release/2023/11/09/2777840/0/en/Sana-Biotechnology-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-SC291-a-Hypoimmune-modified-CD19-directed-Allogeneic-CAR-T-Therapy-for-Patients-with-Lupus-Ne.html免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

ENB-003 in combination with KEYTRUDA® (pembrolizumab) demonstrated encouraging objective responses, disease control and progression-free survival in patients with metastatic platinum refractory/resistant ovarian cancer (PROC) Encouraging results support further development Expansion cohort in primary PROC and other refractory advanced cancers (ENB-003 + KEYTRUDA) to commence in 2024 NEW YORK--(BUSINESS WIRE)-- ENB Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced top-line results from the dual combination arm of the Phase 1b ENBOLDEN-101 study, evaluating ENB-003 in combination with Merck & Co.’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced refractory cancers. The results show encouraging objective responses, disease control and extended progression-free survival in patients with platinum resistant/ refractory ovarian cancer (PROC). The poster, entitled, "ENB-003, an ETBR antagonist, in combination with pembrolizumab, shows promise in microsatellite stable platinum refractory/resistant ovarian cancer: Data from the ENBOLDEN-101 Phase 1B study" was presented on November 3, 2023 at a poster session at the SITC 2023 meeting, was held November 1-5, in San Diego, California, USA. The data included 5 patients with metastatic microsatellite stable (MSS) PROC who had disease progression after one or more previous lines of treatment. Study treatment consisted of an initial 7-day run-in period of ENB-003 monotherapy, followed by repeated 3-week cycles of ENB-003 in combination with KEYTRUDA. The data demonstrated that the treatment regimen was safe and well tolerated. The objective response rate (ORR) and disease control rate (DCR- patients exhibiting a response or stable disease) in MSS PROC was 40% and 80% respectively (N=5), including 2 patients with partial responses showing a 95% and 33% reduction in tumor burden respectively, as well as 4 patients with stable disease; 80% of PROC patients demonstrated shrinkage of target lesions overall. The 8-month progression-free survival rate was 60%. This compares favorably with a historical ~20% progression-free survival data at 6 months for single agent anti-PD1 and an ~8% ORR and an ~22% DCR. "These data, demonstrate that ENB-003 in combination with KEYTRUDA is safe, with encouraging signs of clinical activity and support the combination’s potential to become an effective immunotherapy regimen for MSS primary PROC – a disease that has responded very poorly to available treatments,” stated Sumayah Jamal, MD-Ph.D., President, Chief Scientific Officer, and Co-Founder of ENB Therapeutics. "We are extremely pleased with the top-line results from this ongoing study. We look forward to continuing our collaboration with Merck and anticipate initiating Part 2 of the study next year.” For more information on this Phase 1/2a study, see NCT04205227. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. About ENB-003 ENB-003 is a selective endothelin B receptor (ETBR) inhibitor that, in preclinical studies, enhances efficacy of CAR-T and anti-PD-1 in solid tumors across multiple cancer types in preclinical studies. In an ongoing multi-center Phase 1/2 clinical trial, early efficacy signals suggest that ENB-003 overcomes resistance to pembrolizumab in heavily pre-treated drug resistant cancer patients. The Phase 2 portion of the ENB-003 + pembrolizumab combination study is expected to start in the first half of 2024. The trial will enroll MSS primary PROC, as well as MSS pancreatic cancer patients and patients with other advanced solid tumors that have failed standard of care. About ENB Therapeutics, Inc. ENB Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, endothelin B receptor (ETBR) inhibitors, to overcome resistance to CAR-T in solid tumors and immune-based therapies such as the immune checkpoint inhibitors. ETBR causes uncontrolled cancer growth, drives cancers to spread through the body and prevents the immune system from detecting and killing cancer cells. ENB’s lead product candidate, ENB-003 specifically blocks the ETBR and has the potential to drive the efficacy of CAR-T and anti-PD1 therapies in solid tumors. ENB-003 is currently being investigated in an ongoing Phase 1/2 clinical trial in collaboration with Merck. Learn more by visiting the ENB Therapeutics website. Forward Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the clinical development of ENB-003 or any of ENB’s other product candidates or programs; the design of ENB’s clinical trials; the safety, durability, or efficacy of ENB-003; and the potential benefits of ENB-003 or any of ENB’s other product candidates. ENB may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of ENB’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; expectations for regulatory approvals to conduct trials or to market product; risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as to ENB’s abilities to meet other anticipated deadlines and milestones, presented by the ongoing COVID-19 pandemic; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and ENB expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.